Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel

Reicher, Shay; Ratzon, Ronit; Ben-Sahar, Shay; Hermoni-Alon, Sharon; Mossinson, David; Shenhar, Yotam; Friger, Michael; Lustig, Yaniv; Alroy‐Preis, Sharon; Anis, Emilia; Sadetzki, Siegal; Kaliner, Ehud

doi:10.1007/s10654-021-00749-1

Cited by 36 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with other studies, the lower rates were observed in age classes above 60 years (4,16,21). Since people in these age classes are the main risk group for COVID-19 severe forms, the observed low prevalence may result from their tendency to minimize social interactions.…”

Section: Discussionsupporting

confidence: 89%

Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People

Capai

Masse

Fourié

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

We aimed to use serological surveillance based on serial cross-sectional sampling of residual sera obtained from clinical laboratories to compare the differences in age and sex profiles of infected persons in the first and second waves of SARS-CoV-2 in Corsica, France. Residual sera were obtained, including samples from individuals of all ages collected for routine screening or clinical management by clinical laboratories. All the sera collected were tested for the presence of anti-SARS-CoV-2 IgG using a kit for semi-quantitative detection of IgG antibodies against the S1 domain of the viral spike protein (ELISA-S). Samples that were borderline and positive in ELISA-S were tested with an in-house virus neutralization test. During the second-wave period, we collected between 6 November, 2020 and 12 February, 2021, 4,505 sera from patients aged 0–101 years (60.4% women). The overall weighted seroprevalence of residual sera collected during the second-wave period [8.04% (7.87–9.61)] was significantly higher than the overall weighted seroprevalence estimated at the end of the first wave between 16 April and 15 June, 2020 [5.46% (4.37–7.00)] (p-value = 0.00025). Ninety-eight (30.1%) of the 326 samples tested in the VNT assay had a positive neutralization antibody titer. Estimated seroprevalence increased significantly for men [odds ratio (OR) OR = 1.80 (1.30–2.54); p-value = 0.00026] and for people under 30 years of age [OR = 2.17 (1.46–3.28); p-value = 0.000032]. This increase was observed in young adults aged 20–29 years among whom antibody frequencies were around four-fold higher than those observed at the end of the first wave. In conclusion, our seroprevalence estimates, including the proportion of the participants who had produced neutralizing antibodies, indicate that in February, 2021 the population of Corsica was still far from being protected against SARS-Cov-2 by “herd immunity.”

show abstract

Section: Discussionsupporting

confidence: 89%

Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People

Capai

Masse

Fourié

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…A large, population-based seroepidemiological study out of Wuhan, China, a place of high initial incidence, described similar seroprevalence in children and older age groups [17]. In our cohort, seroprevalence among children increased with age, as had been the case for other cohorts of the ancestral SARS-CoV-2, including a seroprevalence study in a similar time interval from the south of Germany [14,15,[18][19][20]. These findings may have been specific to the ancestral variant of SARS-CoV-2 and the circumstances governing the early 2020 first wave of coronavirus infections including few imported cases followed by lockdown.…”

Section: Discussionsupporting

confidence: 80%

Long-term antibody response to SARS-CoV-2 in children

Dunay

Barroso

Woidy

et al. 2022

Preprint

View full text Add to dashboard Cite

Almost two years into the pandemic and with vaccination of children significantly lagging behind adults, long-term pediatric humoral immune responses to SARS-CoV-2 are understudied. The C19.CHILD Hamburg (COVID-19 Child Health Investigation of Latent Disease) Study is a prospective cohort study designed to identify and follow up children and their household contacts infected in the early 2020 first wave of SARS-CoV-2 infections. We screened 6113 children <18 years by nasopharyngeal swab-PCR in a low-incidence setting after general lockdown, from May 9 to June 30, 2020. 4657 participants underwent antibody testing. Positive tests were followed up by repeated PCR and serological testing of all household contacts over 6 months. In total, the study identified 67 seropositive children (1.44 %), the median time after infection at first presentation was 83 days post-symptom onset (PSO). Follow up of household contacts showed incomplete seroconversion in most families, with higher rates in families with adult index cases compared to pediatric index cases (OR: 1.79, P=0.047). Most importantly, children showed sustained seroconversion up to nine months PSO, and serum antibody concentrations persistently surpassed adult levels (ratio serum IgG Spike children vs. adults 90 days PSO: 1.75, P<0.001, 180 days: 1.38, P=0.01, 270 days: 1.54, P=0.001). In a low-incidence setting, SARS-CoV-2 infection and humoral immune response present distinct patterns in children including higher antibody levels, and lower seroconversion rates in families with pediatric index cases. Children show long-term SARS-CoV-2 antibody responses. These findings are relevant to novel variants with increased disease burden in children, as well as for the planning of age-appropriate vaccination strategies.

show abstract

“…With SARS‐CoV‐2 vaccination becoming more widely available globally, the use of serology as a pandemic control tool could transform from a diagnostic modality to a criterion of vaccination efficacy. 27 …”

Section: Discussionmentioning

confidence: 99%

Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan

Smagul¹,

Esmagambetova

Nusupbaeva³

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Seroprevalence studies are needed to determine the cumulative prevalence of SARS‐CoV‐2 infection and to develop pandemic mitigation strategies. Despite the constant monitoring and surveillance, the true level of infection in the population of Kazakhstan remains unknown. The aim of this study was to determine the sero‐prevalence of SARS‐CoV‐2 in the main cities of Kazakhstan. Methods The research was conducted as a cluster‐randomized cross‐sectional national household study in three cities of Kazakhstan. The study covered the period: from October 24, 2020, to January 11, 2021. A total of 5739 people took part in the study. All participants agreed to be tested for antibodies to IgM/IgG. Demographic characteristics were analyzed. The presence of symptoms of respiratory diseases and the results of polymerase chain reaction (PCR) testing were determined. The antibodies to the SARS‐CoV‐2 virus were detected using the method of enzyme‐linked immunosorbent assay (ELISA). Results There was significant geographic variability with a higher prevalence of IgG/IgM antibodies to SARS‐CoV‐2 in Almaty 57.0%, in Oskemen 60.7% than in Kostanay 39.4%. There were no significant differences in prevalence between men and women ( p ≥ 0.05). In Almaty, only 19% of participants with antibodies reported the presence of respiratory symptoms during a pandemic. At the same time, the percentage of patients with antibodies who had respiratory symptoms was 36% in Oskemen and 27% in Kostanay. Conclusion The findings indicate that despite reasonable level of seroprevalence, the country has not yet reached the baseline minimum of herd immunity scores. The prevalence estimates for asymptomatic or subclinical forms of the disease ranged from 64% to 81%. Thus, given that almost half of the population of Kazakhstan remains vulnerable, the importance of preventive strategies such as social distancing, the use of medical masks, and vaccination to protect the population from the transmission of SARS‐CoV‐2 is highly critical.

show abstract

Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel

Cited by 36 publications

References 28 publications

Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People

Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People

Long-term antibody response to SARS-CoV-2 in children

Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan

Contact Info

Product

Resources

About